This is the authors' abstract. We don't add key points for this paper.
Pleomorphic rhabdomyosarcoma is a rare and aggressive mesenchymal malignancy that occurs predominantly in adults, with no standardised therapeutic protocol and a poor prognosis. We describe a 47-year-old woman who presented with a three-month history of a painful, enlarging mass of the right thigh, initially suggestive of liposarcoma on magnetic resonance imaging. Core needle biopsy established the diagnosis, with immunohistochemical positivity for desmin, myogenin and myoD1 confirming skeletal muscle differentiation. After three cycles of neoadjuvant chemotherapy, wide surgical resection was carried out. The resection specimen showed no dimensional response to treatment, with 75% viable residual tumour. Histological examination confirmed a post-therapeutic residual pleomorphic rhabdomyosarcoma (World Health Organization Classification 2020), graded 3 according to the French Federation of Cancer Centers Sarcoma Group criteria, with a focally positive lateral margin (R1 resection). Negative murine double minute 2 (MDM2) immunohistochemistry argued against dedifferentiated liposarcoma with heterologous rhabdomyoblastic differentiation. Local recurrence developed three months after surgery, before planned adjuvant radiotherapy could be delivered, requiring surgical re-excision; the patient was subsequently lost to follow-up and died one year after diagnosis. This case highlights the diagnostic value of a comprehensive immunohistochemical panel and the prognostic importance of complete surgical excision.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Kouhkouh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: